Page 208 - 北京京煤集团总医院第十届·2022学术年会论文集

北京京煤集团总医院 第十届·2022 学术年会论文集

氟哌噻顿美利曲辛防治胃肠道肿瘤化疗相关恶心呕吐的

临床分析

吴烁，金凤岚， 肖健存（北京京煤集团总医院消化肿瘤科，102300）
【摘要】目的：恶心、呕吐（CINV）是胃肠道恶性肿瘤化疗重要的不良反应之一，常常给

病人带来痛苦，降低患者化疗依从性。为临床降低 CINV 发生提供更多的治疗方法，评估氟
哌噻顿美利曲辛联合 5-羟色胺 3（5-HT3）受体拮抗剂预防胃肠道肿瘤化疗后恶心呕吐的疗

效。方法：选取从 2019 年 1 月-2021 年 10 月来我院就诊的胃肠道恶性肿瘤患者 60 例，采

用前瞻性数字随机对照方法分为 2 组，对照组给予托烷司琼止吐，实验组在此基础上同时口

服氟哌噻顿美利曲辛片，统计分析两组患者恶心呕吐发生情况，比较两组患者食欲改善、体

重变化、KPS 评分变化的差别；结果：实验组预防胃肠道肿瘤 CINV 优于观察组，实验组患

者食欲改善、体重增加情况好于对照组，两组有统计学差异（p<0.05）。结论：氟哌噻顿美

利曲辛片可改善胃肠道恶性肿瘤化疗所致消化道反应，提高止吐疗效，改善患者生活质量，

耐受性好，值得临床应用。

【关键词】氟哌噻顿美利曲辛；胃肠道恶性肿瘤；化疗；恶心呕吐

Clinical observation of Flupentide Melitracine in preventing chemotherapy-related nausea

and vomiting of gastrointestinal cancer
ABSTRACT: Objective: Nausea and vomiting (CINV) is one of the important adverse reactions

of chemotherapy for gastrointestinal cancer, which often brings patients pain and reduces their

compliance with chemotherapy. To provide additional therapeutic options for reducing CINV,

evaluate the efficacy of Flupentixol Melitracine in combination with 5-hydroxytryptamine 3(5-HT3)

receptor antagonist in the prevention of nausea and vomiting following chemotherapy for

gastrointestinal cancer. METHODS: Sixty patients with gastrointestinal malignancies who came to

our hospital from January 2019 to October 2021 were randomly divided into two groups. The

control group was given Tropisetron, on this basis, the patients in the experimental group were given

Flupentixol melitracine orally at the same time. The incidence of nausea and vomiting in the two

groups was statistically analyzed. The differences of appetite improvement, weight change and KPS

score between the two groups were compared. Results: In this study, the effect of Flupentixol

meritracine combined with 5-hydroxytryptamine 3(5-HT3) receptor on the prevention of CINV was

better than that of Control Group. The appetite improvement and weight gain of experimental group

- 203 -